RESI SF Program Guide 1-05-2016
Total Page:16
File Type:pdf, Size:1020Kb
JANUARY 12, 2016 RESI SAN FRANCISCO, CA Early stage investors, fundraising CEOs, scientist-entrepreneurs, strategic partners, and service providers now have an opportunity to Make a Compelling Connection ONSITE GUIDE LIFE SCIENCE NATION Connecting Products, Services & Capital #RESISF2016 | RESIConference.com | January 12, 2016 | Marine's Memorial Club & Hotel 10th floor: Panels, Exhibition elevators & resi innovation challenge Exhibiting resi companies innovators Track 1 - Commandant’s room - BIOTECH 1 2 3 4 5 INVESTOR 1 2 3 4 5 6 7 PANELS 8 17 - regimental room - 21 22 23 24 25 6 18 19 20 21 19 9 20 16 22 23 24 25 7 MEDTECH Track 2 Track 18 30 29 28 27 26 INVESTOR 15 PANELS 17 16 15 14 13 12 11 10 14 13 12 11 10 9 8 13 - Heritage room - 11th floor: partnering forum, Workshops breakfast buffet, LUNCH, Cocktail reception elevators PARTNERING Forum - Crystal Ballroom - Reception WORKSHOPS - Library Room - Food & Beverage - Crystal Lounge - elevators 12th floor: LUNCH 12:00 -1:00 pm - bar - - Service Area - - Leatherneck Steakhouse - Quick guide to each floor 12 PM - 1 PM Lunch (200 Seats) FLOOR 7 AM - 8 AM Breakfast Buffet 8 AM - 5 PM Partnering Forum 8 AM - 5 PM Workshops FLOOR 10 AM - 5 PM Registration 12 PM - 1 PM Lunch (350 Seats) 5 PM - 7 PM Cocktail Reception Sponsored by: Investor Panels 8 AM - 5 PM Exhibition Hall FLOOR RESI Innovation Challenge Registration 7 AM - 10 AM FLOOR (Please register on the 11th floor after 10 AM) content Welcome from Dennis Ford - - - - - - - 2 RESI Schedule - - - - - - - - - - - - - - - - - 3 RESI Innovation Challenge - - - - - - - 4 Exhibiting Companies - - - - - - - - - - 13 Investor Panels - - - - - - - - - - - - - - - 18 Early Stage Workshops - - - - - - - - - 37 Partnering Forum - - - - - - - - - - - - - - 40 Sponsors - - - - - - - - - - - - - - - - - - - - 41 Media Partners - - - - - - - - - - - - - - - 43 General Information - - - - - - - - - - - 44 Notes - - - - - - - - - - - - - - - - - - - - - - 47 1 welcome from dennis ford Life Science Nation (LSN) is thrilled to be back at the annual healthcare conference week for our second RESI San Francisco event. It's the largest RESI conference yet, with over 700 registered attendees, including over 300 early stage global investors! We're delighted that RESI has garnered this enthusiastic audience during a very busy week for the life science industry. We've expanded the bandwidth of RESI Partnering in order to offer more opportunities for RESI attendees to connect with each other face-to-face. By using the RESI Partnering system to nd fellow attendees based on t, you can nd meeting partners who align with your focus. With that match as a basis, RESI is a venue for compelling conversations between startups and investors in the life science space. LSN would like to extend our thanks to the speakers who are participating in RESI's two Investor Panel tracks, and the presenters of the RESI Workshops. We're very glad that you're here to share your expertise with the entrepreneurs and investors who attend RESI. We’d also like to bring your attention to the RESI Innovation Challenge. The RESI Innovators are showcasing cutting-edge life science technologies in poster displays throughout the exhibit hall. Inside your RESI badge you’ll nd ve tokens of RESI Cash you can use to “invest” in the most promising of these technologies. Take the time to invest your RESI Cash wisely, and join us at the evening reception as we announce the winners! Thank you for joining us and making this the biggest RESI yet. We're excited to be here for the rst stop on RESI's 2016 tour. We hope to see you later this year in Houston, Toronto, and Boston. Until then, enjoy the show! Sincerely, Dennis Ford Founder & CEO, Life Science Nation LIFE SCIENCE NATION Connecting Products, Services & Capital 2 resi schedule Track 1: Track 2: Track 3: Track 4: Investor Investor Early Stage Partnering Panels Panels Entrepreneur Forum Workshops - regimental room - - Heritage room - - Library Room - - Crystal Ballroom - 7:00 - 8:00 AM: Registration & Breakfast (Crystal Lounge) LIFE SCIENCE NATION 8:00 Connecting Products, Services & Capital - BIOTECH MEDTECH 8:50 Angels angels fundraising AM boot camp 9:00 Corporate VCs Diagnostic MORNING - & Strategic Non-Dilutive 9:50 investors EARLY STAGE AM Investment Funding PARTNERING 10:00 FORUM - big medtech Realities of translating 10:50 pharma strategics med-tech innovation AM into commercial success 11:00 EARLY STAGE medical device - THERAPEUTICS Crowdfunding 11:50 investors AM INVESTORS & Reg A+ 12:00 - 1:00 PM: Break for Lunch (Crystal Lounge & Leatherneck Steakhouse) 1:00 - venture CONSUMER 1:50 philanthropy HEALTH How to Value PM Your Startup 2:00 Due to the popularity of - BIOTECH medtech AFTERNOON Sessions, there is no 2:50 family offices family offices workshop scheduled to run EARLY STAGE PM during this time slot. PARTNERING 3:00 orphan & rare FORUM tales from - disease boston 3:50 the road PM investors innovation capital LIFE SCIENCE NATION 4:00 asia-pacific healthcare it Connecting Products, Services & Capital - branding & 4:50 investors investors PM messaging 5:00 - 7:00 PM: Cocktail Reception (Crystal(Crystal Ball Lounge)room & Crystal Lounge) 3 resi innovation challenge - Commandant’s room - 10th floor RESI $ Innovation 100,000 Challenge RESI CASH www.RESIConference.com We welcome you to participate in the RESI Innovation Challenge! The RESI Innovation Challenge is a virtual investment contest, and the investor is you! As you explore the exhibit hall, you will encounter 30 RESI Innovators showcasing their technology via poster displays. Along with your RESI attendee badge, you will nd ve RESI Cash tokens that you can use to 'invest' in the most promising RESI Innovators. Take a look around this collection of cutting-edge life science technology, and leave your RESI Cash with the entrepreneurs that most inspire you. The invested capital will be tallied up and the top three winners will be awarded during the cocktail reception at the end of the day. Winners will be featured in the Life Science Nation (LSN) newsletter with readership of 20,000. • FirstLSN Prize: Investor Complimentary Platform for tickets a year. to 3 RESI Conference Series events of your choice (2 tickets per event) • Second Prize: Complimentary tickets to 2 RESI Conference Series events of your choice (2 tickets per event) • Third Prize: Complimentary tickets to 1 RESI Conference Series event of your choice (2 tickets) 4 resi innovation challenge - Commandant’s room - 10th floor RESI Innovators Easel 1 Easel 2 Easel 3 Easel 4 Easel 5 Easel 6 Easel 7 Easel 8 Easel 9 Easel 10 Easel 11 Easel 12 Easel 13 Easel 14 Easel 15 Easel 16 Easel 17 Easel 18 Easel 19 Easel 20 Easel 21 Easel 22 Easel 23 Easel 24 Easel 25 Easel 26 Easel 27 Easel 28 Easel 29 Easel 30 5 resi innovators Easel 1 - 8 Vicus Therapeutics is a clinical-stage immuno-oncology company developing neuro-immune-modulators (“NIMs”) as combination therapies for pancreatic and other solid cancers. Our lead NIM asset, VT-122, is a chrono-formulation of etodolac and propranolol. VT-122 modulates beta adrenergic, peptidergic and prostaglandin signaling cascades to damp tumor promoting inammation and restore immune surveillance. Unlike other immune modulators, VT-122 also improves treatment tolerance. Proof-of-concept has been demonstrated in one Phase 2 and two cohort studies of advanced pancreatic and liver cancers. In 2016, VT-122 will be evaluated as a combination therapeutic in a Phase 2/3 clinical trial for metastatic pancreatic cancer, an indication for which VT-122 was granted an Orphan Drug designation, and as a neo-adjuvant/adjuvant therapeutic in a Phase 2 clinical trial for ovarian cancer. The surgeon’s lack of tactile feedback during minimally invasive laparoscopic and robotic surgery leads to difculty in safely visualizing and manipulating blood vessels, ureters, and bile ducts. Briteseed combats this problem by building smart surgical tools using low-cost optical technology to non-invasively visualize both between and near the jaws of a surgical tool in real time. This combination hardware and software solution is exible enough to be seamlessly integrated into a spectrum of surgical tools. These smart tools will provide imaging and diagnostic capabilities without interrupting surgical workow, increasing user adoption. By raising the quality and decreasing overall cost of care, Briteseed provides value to surgeons and the hospital administrations that support them. NuvOx Pharma is developing a platform of drugs that increase the blood's oxygen carrying capacity and decrease tissue hypoxia. The company has pre-clinical data showing improved outcomes in oncology, sickle cell crisis, stroke, and several other life-threatening indications. A Phase 1b clinical trial is in progress for the rst indication, oncology. A Series A-2 round is currently open. Immunophotonics is developing inCVAX, an in situ autologous cancer vaccine that uses whole tumor cells as the source of antigens from individual patients without ex-vivo preparations. inCVAX utilizes a two injection procedure into one or more tumors: The rst injection is an optical ber (coupled to a laser) that heats a portion of the tumor to induce immunogenic cell death and tumor antigen release. The second injection is our experimental drug, a proprietary synthesized carbohydrate polymer, intended to activate antigen-presenting cells, potentially triggering a systemic anti-tumor immune response. During a rst-in-human clinical trial, several patients experienced shrinkage of local tumors and distant metastases with a favorable safety prole – in some cases this led to a complete response. Accel Diagnostics is developing novel point-of care, smartphone-enabled, diagnostic products addressing the medical need of rapid and accurate diagnostic and monitoring solutions for the growing chronic patients – in primary cares and homes. AccelDx’s proprietary technology, pScreen™, enables doctors and patients to perform lab-quality biomarker blood-based diagnostic tests anytime, anywhere. pScreen™ is transforming the diagnostics paradigm, by bringing signicant advantages in terms of simplicity, time to result, care delivery, and cost.